Tag Archive for: Cybin

Psychedelic Business Spotlight: November 12

,
This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.
Cybin’s Novel Analog Shows Multiple Advantages Over Oral Psilocybin

Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the ‘Superior Molecule’

Pre-clinical studies demonstrated multiple advantages, including less patient variability, faster onset of action, shorter duration of effect, and improved brain penetration.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

,
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Could the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

Can the Psychedelics Boom Go Bust? A Conversation with Cybin Chief Clinical Officer Dr. Alex Belser

"Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.

Psychedelic Business Spotlight: October 29

,
This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
FDA Authorizes Device to Quantify Psychedelics’ Effects on the BrainShutterstock.com

FDA Authorizes Cybin Device to Quantify Psychedelics’ Effects on the Brain

"This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding," says Cybin's chief clinical officer.
Psychedelic Business Spotlight: October 22

Psychedelic Business Spotlight: October 22

,
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.

Psychedelic Business Spotlight: October 15

,
This week in psychedelic business news: Cybin inhales; atai Life Sciences expands; DEA grants new psilocybin license; and FDA backs ketamine.
How Cybin Is 'Revolutionizing' Mental Healthcare with Novel Psychedelic Compounds

How Cybin Is ‘Revolutionizing’ Mental Healthcare with Novel Psychedelic Compounds

CEO Doug Drysdale explains several key factors in making psychedelic-assisted therapy accessible for the millions of people suffering around the globe.

Interview with Doug Drysdale, CEO, Cybin Inc

Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.